A Framework for Evaluating the Clinical Consequences of Initial Therapy with NSAIDs, NSAIDs plus Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis
| Autor: | Jay L. Goldstein, Nikos Maniadakis, Thomas A. Burke, Clement J. Maurath, Richard A. Zabinski, D. Pettitt |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Arthritis Gastroenterology Diclofenac Internal medicine medicine Humans Cyclooxygenase Inhibitors Economics Pharmaceutical skin and connective tissue diseases Adverse effect Misoprostol Probability Pharmacology Clinical Trials as Topic Sulfonamides business.industry Health Policy Anti-Inflammatory Agents Non-Steroidal Decision Trees Public Health Environmental and Occupational Health Anemia Anti-Ulcer Agents medicine.disease digestive system diseases Clinical trial Tolerability Celecoxib Duodenal Ulcer Concomitant Pyrazoles Drug Therapy Combination business medicine.drug |
| Zdroj: | PharmacoEconomics. 19:33-47 |
| ISSN: | 1170-7690 |
| Popis: | Objective: The purpose of this study is to provide a framework for estimating the economic efficiency of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), concomitant gastroprotective agents (GPAs) to reduce the risk of NSAID toxicity, and celecoxib, a specific cyclo-oxygenase-2 inhibitor. Concomitant GPAtherapies considered include one of the following: proton pump inhibitors (PPIs) plus NSAIDs, histamine H2 receptor antagonists (H2RAs) plus NSAIDs, misoprostol plus NSAIDs, and a single tablet formulation of diclofenac/misoprostol. Design: The study employs a decision-tree framework to establish probabilities of upper gastrointestinal (GI) adverse events occurring over a 6-month time frame. Celecoxib clinical trial data are used to establish probabilities of upper GI events for celecoxib and NSAIDs, and published literature is used to predict upper GI events for the other concomitant therapies. Upper GI adverse events included in the decision-tree are as follows: GI discomfort, symptomatic ulcer, serious GI complications (with and without death), and anaemia with occult bleeding. Main outcome measures and results: Clinical probabilities indicate celecoxib has significant tolerability and safety advantages compared with nonselective NSAIDs. Celecoxib also reduces the risk of GI adverse events to a similar or superior degree when compared with reductions observed with NSAIDs with concomitant GPAs. Conclusion: Use of celecoxib is expected to significantly reduce the economic costs of GI toxicity and its associated morbidity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink